AR078462A1 - Inhibidores macrociclicos de la replicacion de virus de la hepatitis c - Google Patents
Inhibidores macrociclicos de la replicacion de virus de la hepatitis cInfo
- Publication number
- AR078462A1 AR078462A1 ARP100103512A ARP100103512A AR078462A1 AR 078462 A1 AR078462 A1 AR 078462A1 AR P100103512 A ARP100103512 A AR P100103512A AR P100103512 A ARP100103512 A AR P100103512A AR 078462 A1 AR078462 A1 AR 078462A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- group
- alkyl
- aryl
- fluoro
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000029812 viral genome replication Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 18
- 125000001153 fluoro group Chemical group F* 0.000 abstract 13
- 125000001072 heteroaryl group Chemical group 0.000 abstract 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 11
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 9
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000001424 substituent group Chemical group 0.000 abstract 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 7
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 5
- 125000003107 substituted aryl group Chemical group 0.000 abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- -1 -C (O) NR'R' ' Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000003367 polycyclic group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000000460 chlorine Chemical group 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24646509P | 2009-09-28 | 2009-09-28 | |
| US32425110P | 2010-04-14 | 2010-04-14 | |
| US34573710P | 2010-05-18 | 2010-05-18 | |
| US34623810P | 2010-05-19 | 2010-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078462A1 true AR078462A1 (es) | 2011-11-09 |
Family
ID=43796242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103512A AR078462A1 (es) | 2009-09-28 | 2010-09-28 | Inhibidores macrociclicos de la replicacion de virus de la hepatitis c |
Country Status (19)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305697A3 (en) * | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
| CA2624333A1 (en) * | 2005-10-11 | 2007-04-19 | Intermune, Inc. | Compounds and methods for inhibiting hepatitis c viral replication |
| US8048862B2 (en) * | 2008-04-15 | 2011-11-01 | Intermune, Inc. | Macrocyclic inhibitors of hepatitis C virus replication |
| CA2740728A1 (en) * | 2008-10-15 | 2010-04-22 | Intermune, Inc. | Therapeutic antiviral peptides |
| WO2011041551A1 (en) * | 2009-10-01 | 2011-04-07 | Intermune, Inc. | Therapeutic antiviral peptides |
| JP6026284B2 (ja) * | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| CA2801584A1 (en) * | 2010-06-07 | 2011-12-15 | Abbvie Inc. | Macrocyclic hepatitis c serine protease inhibitors |
| ES2573412T3 (es) * | 2010-09-10 | 2016-06-07 | Shionogi & Co., Ltd. | Derivado de imidazol de heteroanillo fusionado que tiene efecto de AMPK (activacion de proteina cinasa activada por monofosfato de adenosina) |
| WO2012054874A1 (en) * | 2010-10-22 | 2012-04-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP6235473B2 (ja) * | 2011-09-22 | 2017-11-22 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 大環状ｈｃｖプロテアーゼ阻害剤を製造するための方法および中間体 |
| US20150166528A1 (en) | 2012-06-14 | 2015-06-18 | Basf Se | Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| DK2909205T3 (en) | 2012-10-19 | 2017-03-06 | Bristol Myers Squibb Co | 9-METHYL-SUBSTITUTED HEXADECAHYDROCYCLOPROPA (E) PYRROL (1,2-A) (1,4) DIAZOCYCLOPENTADECINYLCARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR TREATMENT |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014140365A1 (en) * | 2013-03-15 | 2014-09-18 | Syngenta Participations Ag | Microbicidally active imidazopyridine derivatives |
| ES2735355T3 (es) | 2013-03-15 | 2019-12-18 | Gilead Sciences Inc | Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C |
| WO2016127859A1 (en) * | 2015-02-13 | 2016-08-18 | Sunshine Lake Pharma Co., Ltd. | Compounds as hepatitis c inhibitors and uses thereof in medicine |
| CN108314648A (zh) * | 2018-04-12 | 2018-07-24 | 苏州康润医药有限公司 | 4-溴-7-氟异喹啉的合成方法 |
| CN110305018B (zh) * | 2019-06-06 | 2022-07-15 | 浙江普洛家园药业有限公司 | 一种3-溴-2-氟硝基苯的制备方法 |
| CN112358447B (zh) * | 2020-11-16 | 2022-04-12 | 苏州康润医药有限公司 | 7-氟异喹啉-1-羧酸的合成方法 |
| CN114105800B (zh) * | 2021-11-25 | 2023-09-01 | 杭州国瑞生物科技有限公司 | 一种2,3-二氨基苯甲酸甲酯的制备方法 |
| WO2025257072A1 (en) * | 2024-06-14 | 2025-12-18 | Syngenta Crop Protection Ag | Pesticidally active 2-oxobenzimidazole compounds |
| CN119143611A (zh) * | 2024-11-15 | 2024-12-17 | 浙江大学衢州研究院 | 一种n-异丙基对氟苯胺的连续制备方法 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3547119A (en) | 1967-12-08 | 1970-12-15 | Baxter Laboratories Inc | Catheter assembly |
| US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| US3798209A (en) * | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
| US4311137A (en) | 1980-04-30 | 1982-01-19 | Sherwood Medical Industries Inc. | Infusion device |
| US4531937A (en) | 1983-01-24 | 1985-07-30 | Pacesetter Systems, Inc. | Introducer catheter apparatus and method of use |
| CS263951B1 (en) * | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
| US4755173A (en) | 1986-02-25 | 1988-07-05 | Pacesetter Infusion, Ltd. | Soft cannula subcutaneous injection set |
| US5539122A (en) | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5354866A (en) | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| GB8918806D0 (en) * | 1989-08-17 | 1989-09-27 | Shell Int Research | Chiral compounds,their preparation and use |
| US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| CA2605872A1 (en) | 1992-12-29 | 1994-06-30 | Abbott Laboratories | Intermediates for retroviral protease inhibiting compounds |
| US5545143A (en) | 1993-01-21 | 1996-08-13 | T. S. I. Medical | Device for subcutaneous medication delivery |
| US5624949A (en) * | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| US6693072B2 (en) * | 1994-06-02 | 2004-02-17 | Aventis Pharmaceuticals Inc. | Elastase inhibitors |
| US5756466A (en) * | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US6090822A (en) | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
| US6232333B1 (en) | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6277830B1 (en) | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
| US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| US7256005B2 (en) | 1999-08-10 | 2007-08-14 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity |
| CZ20023321A3 (cs) * | 2000-04-05 | 2003-01-15 | Schering Corporation | Makrocyklická sloučenina a farmaceutický prostředek |
| CN101580536A (zh) * | 2000-04-19 | 2009-11-18 | 先灵公司 | 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂 |
| US7012066B2 (en) * | 2000-07-21 | 2006-03-14 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| JP3889708B2 (ja) * | 2000-11-20 | 2007-03-07 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎トリペプチド阻害剤 |
| DE60229059D1 (de) * | 2001-05-08 | 2008-11-06 | Univ Yale | Proteomimetische verbindungen und verfahren |
| US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| EP1497282A2 (en) * | 2002-04-11 | 2005-01-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4 protease |
| PL215228B1 (pl) * | 2002-05-20 | 2013-11-29 | Bristol Myers Squibb Co | Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie |
| ES2350201T3 (es) * | 2002-05-20 | 2011-01-20 | Bristol-Myers Squibb Company | Sulfamidas heterocíclicas como inhibidores del virus de la hepatitis c. |
| WO2004043339A2 (en) * | 2002-05-20 | 2004-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| PL199412B1 (pl) * | 2002-10-15 | 2008-09-30 | Boehringer Ingelheim Int | Nowe kompleksy rutenu jako (pre)katalizatory reakcji metatezy, pochodne 2-alkoksy-5-nitrostyrenu jako związki pośrednie i sposób ich wytwarzania |
| CA2522205A1 (en) * | 2003-04-10 | 2004-10-28 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
| TW200510391A (en) * | 2003-04-11 | 2005-03-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| DE602004019518D1 (de) * | 2003-04-16 | 2009-04-02 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
| EP2143727B1 (en) * | 2003-04-18 | 2015-01-21 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| CA2541634A1 (en) * | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| RS20060259A (sr) * | 2003-10-14 | 2008-08-07 | Intermune Inc., | Makrociklične karboksilne kiseline i acilsulfonamidi kao inhibitori replikacije hcv |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| US7939538B2 (en) * | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
| DE102004033312A1 (de) * | 2004-07-08 | 2006-01-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren |
| WO2006007708A1 (en) * | 2004-07-20 | 2006-01-26 | Boehringer Engelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
| MX2007002371A (es) * | 2004-08-27 | 2007-04-23 | Schering Corp | Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. |
| US7189844B2 (en) * | 2004-09-17 | 2007-03-13 | Boehringer Ingelheim International Gmbh | Ring-closing metathesis process in supercritical fluid |
| CA2606195C (en) * | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Hcv ns3 protease inhibitors |
| US7608592B2 (en) * | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
| US7601686B2 (en) * | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) * | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| US7470664B2 (en) * | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
| EP2305697A3 (en) * | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
| PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| TW200745061A (en) * | 2005-07-29 | 2007-12-16 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis C virus |
| CN101277950B (zh) * | 2005-08-02 | 2013-03-27 | 弗特克斯药品有限公司 | 丝氨酸蛋白酶抑制剂 |
| CA2624333A1 (en) * | 2005-10-11 | 2007-04-19 | Intermune, Inc. | Compounds and methods for inhibiting hepatitis c viral replication |
| US7772183B2 (en) * | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP1951717A1 (en) * | 2005-11-16 | 2008-08-06 | F.Hoffmann-La Roche Ag | Novel pyrrolidine derivatives as inhibitors of coagulation factor xa |
| US7728148B2 (en) * | 2006-06-06 | 2010-06-01 | Enanta Pharmaceuticals, Inc. | Acyclic oximyl hepatitis C protease inhibitors |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| EP2049474B1 (en) * | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| DK2041156T3 (en) * | 2006-07-13 | 2014-02-24 | Achillion Pharmaceuticals Inc | 4-AMINO-4-OXOBUTANOYL Peptides AS INHIBITORS OF VIRUS REPLICATION |
| US7718612B2 (en) * | 2007-08-02 | 2010-05-18 | Enanta Pharmaceuticals, Inc. | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
| US20090035267A1 (en) * | 2007-07-31 | 2009-02-05 | Moore Joel D | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors |
| US7635683B2 (en) * | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| CA2656816A1 (en) * | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| US7662779B2 (en) * | 2006-08-11 | 2010-02-16 | Enanta Pharmaceuticals, Inc. | Triazolyl macrocyclic hepatitis C serine protease inhibitors |
| US7582605B2 (en) * | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
| US7687459B2 (en) * | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
| US7605126B2 (en) * | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
| US20080038225A1 (en) * | 2006-08-11 | 2008-02-14 | Ying Sun | Triazolyl acyclic hepatitis c serine protease inhibitors |
| US20090035268A1 (en) * | 2007-08-01 | 2009-02-05 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
| US20090098085A1 (en) * | 2006-08-11 | 2009-04-16 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
| US20080107625A1 (en) * | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
| US8343477B2 (en) * | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) * | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI406660B (zh) * | 2006-11-17 | 2013-09-01 | Tibotec Pharm Ltd | Ｃ型肝炎病毒之巨環抑制劑 |
| US20100087382A1 (en) * | 2007-02-16 | 2010-04-08 | Boehringer Ingelheim International Gmbh | Inhibitors of Hepatitis C NS3 Protease |
| CN101679240A (zh) * | 2007-03-23 | 2010-03-24 | 先灵公司 | Hcv ns3蛋白酶的p1-非可差向异构化酮酰胺抑制剂 |
| US20090123423A1 (en) * | 2007-04-26 | 2009-05-14 | Yonghua Gai | Hydroxyamic analogs as hepatitis c virus serine protease inhibitor |
| JP2010528987A (ja) | 2007-05-03 | 2010-08-26 | インターミューン・インコーポレーテッド | Ｃ型肝炎ウイルス複製の新規大環状阻害剤 |
| US8093257B2 (en) * | 2007-05-04 | 2012-01-10 | Bristol-Myers Squibb Company | [6,5]-bicyclic GPR119 G protein-coupled receptor agonists |
| US7932277B2 (en) * | 2007-05-10 | 2011-04-26 | Intermune, Inc. | Peptide inhibitors of hepatitis C virus replication |
| US20090005387A1 (en) * | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
| BRPI0813733A2 (pt) * | 2007-06-29 | 2019-11-05 | Gilead Sciences Inc | composto com atividade inibidora de hcv, sua composição farmacêutica e seu uso. |
| WO2009014730A1 (en) * | 2007-07-26 | 2009-01-29 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US20090053175A1 (en) * | 2007-08-24 | 2009-02-26 | Yat Sun Or | Substitute pyrrolidine derivatives |
| US20090060874A1 (en) * | 2007-09-05 | 2009-03-05 | Yao-Ling Qiu | Bicyclic pyrrolidine derivatives |
| EP2190858A4 (en) * | 2007-09-24 | 2013-02-13 | Achillion Pharmaceuticals Inc | PEPTIDES CONTAINING UREA AS INHIBITORS OF VIRAL REPLICATION |
| US20090082366A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched telaprevir |
| MX2010003916A (es) * | 2007-10-10 | 2010-05-05 | Novartis Ag | Espiro-pirrolidinas y su uso contra infeccion por el virus de hepatitis c (hcv) y por el virus de inmunodeficiencia humana (vih). |
| WO2009055335A2 (en) * | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
| US8383583B2 (en) * | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| US20090175824A1 (en) * | 2007-11-20 | 2009-07-09 | Craig Masse | Peptides for the treatment of HCV infections |
| WO2009080542A1 (en) * | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Process for the preparation of a macrocycle |
| US8048862B2 (en) * | 2008-04-15 | 2011-11-01 | Intermune, Inc. | Macrocyclic inhibitors of hepatitis C virus replication |
| CN102177172A (zh) * | 2008-07-02 | 2011-09-07 | 埃迪尼克斯医药公司 | 用于治疗病毒感染的化合物和药物组合物 |
| CA2732091A1 (en) * | 2008-08-07 | 2010-02-11 | F. Hoffmann-La Roche Ag | Process for the preparation of a macrocycle |
| US7906655B2 (en) * | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| UY32099A (es) * | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| AU2009293493B2 (en) * | 2008-09-17 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Combination of HCV NS3 protease inhibitor with interferon and ribavirin |
| US8603737B2 (en) * | 2008-09-19 | 2013-12-10 | Celgene Avilomics Research, Inc. | Methods for identifying HCV protease inhibitors |
| US20100080770A1 (en) * | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8044087B2 (en) * | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) * | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2740728A1 (en) * | 2008-10-15 | 2010-04-22 | Intermune, Inc. | Therapeutic antiviral peptides |
| WO2010059937A1 (en) * | 2008-11-20 | 2010-05-27 | Achillion Pharmaceuticals, Inc. | Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus |
| US20110064694A1 (en) * | 2009-09-09 | 2011-03-17 | Yale University | Anti-hepatitis c activity of meso-tetrakis-porphyrin analogues |
| US8703938B2 (en) * | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| EP2475256A4 (en) * | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8815928B2 (en) * | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8822700B2 (en) * | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8927709B2 (en) * | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8759332B2 (en) * | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| AU2009352688B2 (en) * | 2009-09-15 | 2014-04-17 | Taigen Biotechnology Co., Ltd. | HCV protease inhibitors |
| WO2011041551A1 (en) * | 2009-10-01 | 2011-04-07 | Intermune, Inc. | Therapeutic antiviral peptides |
-
2010
- 2010-09-24 KR KR1020127010337A patent/KR20130026410A/ko not_active Withdrawn
- 2010-09-24 CN CN201080053601.9A patent/CN102741270B/zh not_active Expired - Fee Related
- 2010-09-24 IN IN2693DEN2012 patent/IN2012DN02693A/en unknown
- 2010-09-24 JP JP2012531086A patent/JP2013505952A/ja not_active Withdrawn
- 2010-09-24 EA EA201290128A patent/EA201290128A1/ru unknown
- 2010-09-24 MX MX2012003500A patent/MX2012003500A/es not_active Application Discontinuation
- 2010-09-24 CA CA2775697A patent/CA2775697A1/en not_active Abandoned
- 2010-09-24 PH PH1/2012/500602A patent/PH12012500602A1/en unknown
- 2010-09-24 CN CN201510341151.8A patent/CN105001302A/zh active Pending
- 2010-09-24 WO PCT/US2010/050298 patent/WO2011038293A1/en not_active Ceased
- 2010-09-24 EP EP10819571.0A patent/EP2483290A4/en not_active Withdrawn
- 2010-09-24 AU AU2010298028A patent/AU2010298028A1/en not_active Abandoned
- 2010-09-24 US US12/890,475 patent/US20110081315A1/en not_active Abandoned
- 2010-09-28 AR ARP100103512A patent/AR078462A1/es unknown
- 2010-09-28 TW TW099132976A patent/TW201124137A/zh unknown
-
2012
- 2012-03-21 IL IL218766A patent/IL218766A0/en unknown
- 2012-03-27 TN TNP2012000135A patent/TN2012000135A1/en unknown
- 2012-04-26 MA MA34813A patent/MA33720B1/fr unknown
- 2012-04-27 EC ECSP12011845 patent/ECSP12011845A/es unknown
- 2012-04-27 CO CO12069712A patent/CO6531497A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2483290A1 (en) | 2012-08-08 |
| PH12012500602A1 (en) | 2017-08-23 |
| TN2012000135A1 (en) | 2013-09-19 |
| MX2012003500A (es) | 2012-08-01 |
| EP2483290A4 (en) | 2013-05-01 |
| IL218766A0 (en) | 2012-06-28 |
| CN105001302A (zh) | 2015-10-28 |
| CO6531497A2 (es) | 2012-09-28 |
| CN102741270B (zh) | 2015-07-22 |
| MA33720B1 (fr) | 2012-11-01 |
| TW201124137A (en) | 2011-07-16 |
| KR20130026410A (en) | 2013-03-13 |
| IN2012DN02693A (cg-RX-API-DMAC7.html) | 2015-09-04 |
| CA2775697A1 (en) | 2011-03-31 |
| JP2013505952A (ja) | 2013-02-21 |
| ECSP12011845A (es) | 2012-06-29 |
| CN102741270A (zh) | 2012-10-17 |
| AU2010298028A2 (en) | 2012-10-04 |
| US20110081315A1 (en) | 2011-04-07 |
| EA201290128A1 (ru) | 2013-01-30 |
| AU2010298028A1 (en) | 2012-04-19 |
| WO2011038293A1 (en) | 2011-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078462A1 (es) | Inhibidores macrociclicos de la replicacion de virus de la hepatitis c | |
| AR061642A1 (es) | Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas | |
| CY1123991T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
| CY1124206T1 (el) | Αναστολεις πυριδοπυριμδινονης cdk2/4/6 | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| ES2655391T3 (es) | Inhibidores isoindolinona de fosfatidilinositol 3-quinasa | |
| AR083161A1 (es) | Inhibidores macrociclicos de la replicacion del virus de la hepatitis c, composiciones farmaceuticas que los comprenden, su uso en medicamentos, intermediarios de su sintesis y metodos de preparacion de los mismos | |
| AR083876A1 (es) | 5-halogenopirazolcarboxamidas | |
| AR079648A1 (es) | Inhibidores de la replicacion del virus de la hepatitis c | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| AR061374A1 (es) | Derivados de diamidas de acido antranilico con sus sustituyentes heteroaromaticos y heterociclicos | |
| UY30874A1 (es) | Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapéutica. | |
| PE20131343A1 (es) | Derivados de acido benzoico | |
| CY1114141T1 (el) | Ενωσεις που εχουν ανταγωνιστικη του crth2 δραστηριοτητα | |
| AR056195A1 (es) | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos | |
| AR085489A1 (es) | Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias | |
| AR061739A1 (es) | Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| PE20141205A1 (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2 | |
| AR048032A1 (es) | Compuestos de bifenilo utiles como antagonistas de receptores muscarinicos, un proceso para su preparacion, composiciones farmaceuticas que los contienen, su uso en la fabricacion de un medicamento para el tratamiento de afecciones pulmonares y un metodo para estudiar una muestra biologica que los c | |
| AR072184A1 (es) | Derivados de oxadiazol como agonistas del receptor s1p1 | |
| PE20170323A1 (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| AR072726A1 (es) | Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c | |
| PE20110196A1 (es) | 5-alquinil-pirimidinas | |
| CY1119289T1 (el) | Παραγωγα 1,3-διυδρο-2η-βενζιμιδαζολ-2-ονης υποκατεστημενα με ετεροκυκλικους δακτυλιους ως αντι-ιικοι παραγοντες αναπνευστικου συγκυτιακου ιου |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |